Harmony Biosciences Share Price (NASDAQ: HRMY)

$37.89

▲

0.6

(1.61%)

Last updated on August 23, 2025 at 1:29 AM IST

$₹

Check the interactive Harmony Biosciences Stock chart to analyse performance

Harmony Biosciences stock performance

as on August 23, 2025 at 1:29 AM IST

Today's Low:$37.36
Today's High:$37.97
$37.89
1.4%
Downside
Day's Volatility :1.59%
Upside
0.2%
52 Weeks Low:$26.47
52 Weeks High:$41.61
$37.89
30.14%
Downside
52 Weeks Volatility :36.39%
Upside
8.94%

Harmony Biosciences Stock Returns

Period	Harmony Biosciences Holdings Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	12.04%	6.0%	0.0%
6 Months	10.77%	-5.6%	0.0%
1 Year	4.13%	-11.1%	0.0%
3 Years	-19.26%	6.8%	-7.8%

Harmony Biosciences Holdings Inc Key Stats

Check Harmony Biosciences key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$37.29
Open	$37.42
Today's High	$37.965
Today's Low	$37.36
Market Capitalization	$2.1B
Today's Volume	$491.9K
52 Week High	$41.61
52 Week Low	$26.47
Revenue TTM	$772.5M
EBITDA	$245.7M
Earnings Per Share (EPS)	$3.1
PE Ratio	12.03
Profit Margin	23.42%
Quarterly Earnings Growth YOY	2.4%
Return On Equity TTM	27.58%

Stock Returns calculator for Harmony Biosciences Stock including INR - Dollar returns

The Harmony Biosciences stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Harmony Biosciences investment value today

Current value as on today

₹1,08,524

Returns

₹8,524

(+8.52%)

Returns from Harmony Biosciences Stock

₹4,208 (+4.21%)

Dollar Returns*

₹4,316 (+4.32%)

Indian investors sentiment towards Harmony Biosciences Stock

-3%

Period: Jul 23, 2025 to Aug 22, 2025. Change in 30 Days versus previous period

Search interest for Harmony Biosciences Stock from India on INDmoney has decreased by -3% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Harmony Biosciences Holdings Inc

Name
Holdings %
Name
Holdings %
Valor Management LLC
11.50%
BlackRock Inc
11.32%
FMR Inc
9.29%
Vanguard Group Inc
8.88%
Dimensional Fund Advisors, Inc.
2.75%
State Street Corp
2.74%

Analyst Recommendation on Harmony Biosciences Stock

Rating

Trend

Buy

78%Buy

7%Hold

14%Sell

Based on 14 Wall street analysts offering stock ratings for Harmony Biosciences(by analysts ranked 0 to 5 stars)

Harmony Biosciences Share Price Target

What analysts predicted

Upside of 33.4%

Target:

$50.55

Current:

$37.89

Harmony Biosciences share price target is $50.55, a slight Upside of 33.4% compared to current price of $37.89 as per analysts' prediction.

Harmony Biosciences Stock Insights

Price Movement
In the last 1 month, HRMY stock has moved up by 1.7%
Increasing Revenue
Revenue is up for the last 2 quarters, 184.73M → 200.48M (in $), with an average increase of 7.9% per quarter
Decreasing Net Profit
Netprofit is down for the last 3 quarters, 49.47M → 39.77M (in $), with an average decrease of 10.3% per quarter
HRMY vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 66.6% return, outperforming this stock by 62.5%
HRMY vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 109.5% return, outperforming this stock by 129.3%
Price to Sales
ForHRMY every $1 of sales, investors are willing to pay $2.8, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.9 for every $1 of sales.

Harmony Biosciences Holdings Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$6.0M	-
Net Income	$-158.1M	↑ 296.14%
Net Profit Margin	-2.6K%	-

	FY20	Y/Y Change
Revenue	$159.7M	↑ 2564.59%
Net Income	$-51.9M	↓ 67.19%
Net Profit Margin	-32.46%	↑ 2603.9%

	FY21	Y/Y Change
Revenue	$305.4M	↑ 91.21%
Net Income	$34.6M	↓ 166.72%
Net Profit Margin	11.33%	↑ 43.79%

	FY22	Y/Y Change
Revenue	$437.9M	↑ 43.35%
Net Income	$181.5M	↑ 424.52%
Net Profit Margin	41.44%	↑ 30.11%

	FY23	Y/Y Change
Revenue	$582.0M	↑ 32.93%
Net Income	$128.9M	↓ 28.99%
Net Profit Margin	22.14%	↓ 19.3%

	FY24	Y/Y Change
Revenue	$714.7M	↑ 22.8%
Net Income	$145.5M	↑ 12.91%
Net Profit Margin	20.36%	↓ 1.78%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$154.6M	↓ 8.19%
Net Income	$38.3M	↑ 44.07%
Net Profit Margin	24.79%	↑ 8.99%

	Q2 FY24	Q/Q Change
Revenue	$172.8M	↑ 11.77%
Net Income	$11.6M	↓ 69.76%
Net Profit Margin	6.71%	↓ 18.08%

	Q3 FY24	Q/Q Change
Revenue	$186.0M	↑ 7.65%
Net Income	$46.1M	↑ 297.66%
Net Profit Margin	24.78%	↑ 18.07%

	Q4 FY24	Q/Q Change
Revenue	$201.3M	↑ 8.19%
Net Income	$49.5M	↑ 7.34%
Net Profit Margin	24.58%	↓ 0.2%

	Q1 FY25	Q/Q Change
Revenue	$184.7M	↓ 8.21%
Net Income	$45.6M	↓ 7.91%
Net Profit Margin	24.66%	↑ 0.08%

	Q2 FY25	Q/Q Change
Revenue	$200.5M	↑ 8.53%
Net Income	$39.8M	↓ 12.7%
Net Profit Margin	19.84%	↓ 4.82%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$4.4M	↓ 2501.09%

	FY20	Y/Y Change
Profit	$132.0M	↑ 2887.87%

	FY21	Y/Y Change
Profit	$249.9M	↑ 89.33%

	FY22	Y/Y Change
Profit	$354.4M	↑ 41.79%

	FY23	Y/Y Change
Profit	$460.8M	↑ 30.03%

	FY24	Y/Y Change
Profit	$557.9M	↑ 21.08%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$121.2M	↓ 3.27%

	Q2 FY24	Q/Q Change
Profit	$134.7M	↑ 11.17%

	Q3 FY24	Q/Q Change
Profit	$143.3M	↑ 6.35%

	Q4 FY24	Q/Q Change
Profit	$146.9M	↑ 2.51%

	Q1 FY25	Q/Q Change
Profit	$152.7M	↑ 4.0%

	Q2 FY25	Q/Q Change
Profit	$162.3M	↑ 6.28%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-75.4M	↑ 94.43%
Investing Cash Flow	$-127.1M	↑ 9374.59%
Financing Cash Flow	$143.8M	↑ 565.14%

	FY20	Y/Y Change
Operating Cash Flow	$-3.0M	↓ 96.04%
Investing Cash Flow	$-2.0M	↓ 98.43%
Financing Cash Flow	$209.2M	↑ 45.48%

	FY21	Y/Y Change
Operating Cash Flow	$98.6M	↓ 3401.74%
Investing Cash Flow	$-100.3M	↑ 4909.89%
Financing Cash Flow	$7.4M	↓ 96.45%

	FY22	Y/Y Change
Operating Cash Flow	$144.5M	↑ 46.58%
Investing Cash Flow	$-141.8M	↑ 41.41%
Financing Cash Flow	$6.8M	↓ 7.79%

	FY23	Y/Y Change
Operating Cash Flow	$219.4M	↑ 51.86%
Investing Cash Flow	$-46.4M	↓ 67.26%
Financing Cash Flow	$-105.6M	↓ 1642.93%

	FY24	Y/Y Change
Operating Cash Flow	$219.8M	↑ 0.2%
Investing Cash Flow	$-67.5M	↑ 45.32%
Financing Cash Flow	$-11.0M	↓ 89.58%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$31.1M	↓ 59.38%
Investing Cash Flow	$-6.2M	↓ 82.85%
Financing Cash Flow	$-3.6M	↓ 93.21%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$42.6M	↑ 36.85%
Investing Cash Flow	$-54.9M	↑ 786.78%
Financing Cash Flow	$-3.4M	↓ 5.17%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$70.5M	↑ 65.43%
Investing Cash Flow	$745.0K	↓ 101.36%
Financing Cash Flow	$-1.2M	↓ 65.9%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$75.6M	↑ 7.18%
Investing Cash Flow	$-7.2M	↓ 1064.7%
Financing Cash Flow	$-2.7M	↑ 133.28%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$34.0M	↓ 55.02%
Investing Cash Flow	$2.4M	↓ 132.86%
Financing Cash Flow	$-352.0K	↓ 87.16%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$79.3M	↑ 133.4%
Investing Cash Flow	$-19.6M	↓ 929.34%
Financing Cash Flow	$-2.7M	↑ 663.07%

Harmony Biosciences Technicals Summary

Sell

Neutral

Buy

Harmony Biosciences is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Harmony Biosciences Holdings Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Harmony Biosciences Holdings Inc	3.13%	10.77%	4.13%	-19.26%	11.35%
Regeneron Pharmaceuticals, Inc.	4.38%	-17.37%	-50.85%	-2.23%	-0.91%
Beone Medicines Ltd	5.81%	21.35%	61.84%	78.01%	32.14%
Vertex Pharmaceuticals Incorporated	-16.34%	-17.97%	-17.9%	35.76%	47.74%
Alnylam Pharmaceuticals, Inc.	38.5%	82.49%	66.63%	105.56%	244.81%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Harmony Biosciences Holdings Inc	12.03	12.03	NA	3.96	0.28	0.14	NA	13.44
Regeneron Pharmaceuticals, Inc.	15.08	15.08	1.23	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.29	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	28.25	28.25	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Harmony Biosciences Holdings Inc	Buy	$2.1B	11.35%	12.03	23.42%
Regeneron Pharmaceuticals, Inc.	Buy	$63.4B	-0.91%	15.08	31.37%
Beone Medicines Ltd	NA	$38.2B	32.14%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$101.9B	47.74%	28.25	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$60.1B	244.81%	NA	-12.96%

About Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 1 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome (FXS), rare genetic disorder that causes inherited intellectual disability and autism spectrum disorder; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; and EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies (DEE). The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Organization	Harmony Biosciences
Employees	268
CEO	Dr. Jeffrey M. Dayno M.D.
Industry	Health Technology

Key Management of Harmony Biosciences Holdings Inc

Name	Title
Mr. Jeffrey S. Aronin	Founder & Non-Executive Chairman
Dr. Jeffrey M. Dayno M.D.	President, CEO & Director
Mr. Sandip S. Kapadia CPA, M.B.A.	Executive VP, Chief Administrative Officer & CFO
Dr. Kumar Budur M.D., M.S.	Executive VP and Chief Medical & Scientific Officer
Mr. Andrew Serafin J.D., M.B.A.	Executive VP & Chief Strategy Officer
Brennan Doyle	VP & Head of Investor Relations
Mr. Christian Ulrich J.D.	General Counsel & Corporate Secretary
Ms. Tricia Glover	Chief Compliance Officer
Ms. Audrey Murphy SPHR	Chief Human Resources Officer
Ms. Cate McCanless	Senior VP & Chief Corporate Affairs Officer

Important FAQs about investing in HRMY Stock from India :

What is Harmony Biosciences share price today?

Harmony Biosciences share price today is $37.89 as on August 23, 2025 at 1:29 AM IST at the close of the market. Harmony Biosciences share today touched a day high of $37.97 and a low of $37.36.

What is the 52 week high and 52 week low for Harmony Biosciences share?

Harmony Biosciences share touched a 52 week high of $41.61 and a 52 week low of $26.47. Harmony Biosciences stock price today i.e. August 23, 2025 at 1:29 AM IST is closed at $37.89, lower by 8.94% versus the 52 week high.

How to invest in Harmony Biosciences Stock (HRMY) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Harmony Biosciences on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Harmony Biosciences Shares that will get you 0.0396 shares as per Harmony Biosciences share price of $37.89 per share as on August 23, 2025 at 1:29 AM IST.

What is the minimum amount required to buy Harmony Biosciences Stock (HRMY) from India?

Indian investors can start investing in Harmony Biosciences (HRMY) shares with as little as ₹87.521 or $1 (as of August 23, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹875.21 in Harmony Biosciences stock (as per the Rupee-Dollar exchange rate as on August 23, 2025). Based on Harmony Biosciences share’s latest price of $37.89 as on August 23, 2025 at 1:29 AM IST, you will get 0.2639 shares of Harmony Biosciences. Learn more about fractional shares .

What are the returns that Harmony Biosciences has given to Indian investors in the last 5 years?

Harmony Biosciences stock has given 11.35% share price returns and 18.0% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your US Stock Investments?